APSR2026-159

 
Late-Breaking
Submitted
Poster Presentation
 
AP02-007
P15
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1211566-46904-Azithromicin Low Dose Research APSR 30th Robby_434467.pdf
Format: PDF Only
05. Respiratory Infections (non-tuberculous)
5

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Dwi Robbiardy Eksa * Malahayati University Department of Pulmonology and Respiratory Medicine Bandar Lampung Indonesia
Retno Ariza S Soemarwoto - University of Lampung Department of Pulmonology and Respiratory Medicine Bandar Lampung Indonesia
Andreas Infianto - University of Lampung Department of Pulmonology and Respiratory Medicine Bandar Lampung Indonesia
Reza Permana Putra - University of Lampung Department of Pulmonology and Respiratory Medicine Bandar Lampung Indonesia
Rizki Putra Sanjaya - Dr. Bob Bazar General Hospital Department of Pulmonology and Respiratory Medicine South Lampung Regency Indonesia
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Dwi Robbiardy
Eksa
robbiardy@malahayati.ac.id
+6282127755555
41-50
Indonesia
Original Research
Randomized Controlled Trial of Low-Dose Azithromycin Evaluating Pre–Post Changes in Length of Hospital Stay in Pneumonia
Maximum 25 words
Abstract Content
Pneumonia remains a leading cause of morbidity and inpatient healthcare utilization.1 In addition to its antimicrobial activity, azithromycin has immunomodulatory properties that may attenuate excessive inflammatory responses.2 Evidence regarding the clinical benefits of low-dose azithromycin on hospitalization outcomes and inflammatory markers is still evolving.3 This study aimed to evaluate the effect of low-dose azithromycin on length of hospital stay and blood neutrophil levels in hospitalized patients with pneumonia.
An experimental analytic study using a randomized controlled trial with a pre–post group design was conducted at Abdul Moeloek Hospital, Lampung Province, from September 2025 to January 2026. Eligible patients hospitalized with pneumonia were randomly allocated to a treatment group (low-dose azithromycin plus standard empiric therapy) or a control group (standard empiric therapy alone). The primary outcomes were length of hospital stay and pre–post changes in blood neutrophil levels. Comparative statistical analyses were performed between groups, with significance set at p < 0.05.
The azithromycin group demonstrated a shorter mean length of stay compared with the control group (3.73 ± 1.03 vs 5.20 ± 1.52 days). Blood neutrophil levels decreased more markedly in the treatment group (85.45 ± 8.50 to 74.36 ± 5.73), whereas the control group showed a smaller reduction (85.41 ± 10.34 to 80.69 ± 9.92), indicating a greater reduction in systemic inflammatory response. The difference in length of stay between groups was statistically significant (p = 0.006; 95% CI).
Low-dose azithromycin administration was associated with reduced hospitalization duration and greater improvement in neutrophil levels. These findings suggest that low-dose azithromycin may provide adjunctive clinical benefits in hospitalized patients with pneumonia.
 
 
 
 
 
Yes
No
 
JPG or JPEG or PNG format ONLY
pneumonia, low-dose azithromycin, length of stay
maximum 3 keywords and no abbreviations, separated by commas
References : 1. Sharma, L., Losier, A., Tolbert, T., Dela Cruz, C.S. and Marion, C.R., 2017. Atypical pneumonia: updates on Legionella, Chlamydophila, and Mycoplasma pneumonia. Clinical Chest Medicine, 38(1), pp.45–58. 2. Yan, Y., Yang, G., Fan, X., Zhang, Y., Liu, F. and Hu, X., 2023. Immunomodulatory role of azithromycin: Potential mechanisms and clinical benefits. Frontiers in Pharmacology. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030824/ 3. Lendermon, E.A., Coon, T.A., Bednash, J.S., Weathington, N.M., McDyer, J.F. and Mallampalli, R.K., 2017. Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome-dependent inflammation. Respiratory Research, 18(1), pp.1–8. Declaration of Conflict of Interest: The presenting author declares no conflicts of interest related to this study. All co-authors have disclosed no potential conflicts of interest. Funding / Sponsorship: This study received no financial support from tobacco or tobacco-related industries. The research was conducted without external commercial sponsorship. All authors declare that there was no industry involvement influencing the study design, data collection, analysis, interpretation, or manuscript preparation. Copyright / Ethical Statement: The presenting author confirms that the content of this abstract is original, does not infringe upon any copyright or third-party rights, and has been approved by all co-authors.
272